Pancreatic cancer is still one of oncology's hardest problems to crack. COMED took part in the Pancreatic Cancer Europe Masterclass for Healthcare Professionals this spring, marking ten years of PCE's work on one of the field's most urgent unmet needs.
Our CSO, Nezih Hekim, PhD, walked through our first-in-class antibody approach to KRAS G12V—a mutation that has proven resistant to conventional treatment strategies for years. The room brought together healthcare professionals from across Europe, and that kind of cross-border exchange is often where real clinical progress starts to take shape.
Thank you to Malta's Minister for Health and Active Ageing for the invitation, and to Pancreatic Cancer Europe for creating a space where clinical need and scientific innovation actually meet.